Spots Global Cancer Trial Database for RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Official Title: Phase I/II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Study ID: NCT00576680

Conditions

Pancreatic Neuroendocrine Tumor

Interventions

RAD001

Temozolomide

Study Description

Brief Summary: This research study will test the safety of RAD001 in combination with temozolomide.

Detailed Description: * Participants will take RAD001 by mouth daily. They will also take temozolomide by mouth daily for one week, followed by a one-week break period. This one-week on/one week off schedule for temozolomide will continue for the duration of the treatment. * After the first month of treatment, there will be a 7-day observation period during which no study medication will be taken to observe for any side effects. * During all treatment cycles (1 cycle is 28 days in length) participants will have a physical exam and will be asked questions about their general health and specific questions about any problems they may be experiencing. Initially, participants will come in every other week. At each of these visits, blood work will be taken to monitor the participants health. * After every 2 months of treatment, participants will have a CT scan or MRI done to see how the medication is working.